AEHR Stock Surges As Earnings Beat Ignites AI And EV Hype

Aehr Test Systems rallied as bullish analyst coverage and robust semiconductor demand lifted sentiment, and stocks have been trading up by 21.11 percent.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading AEHR

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Fiscal Q4 for AEHR showed 33% year-over-year revenue growth to about $18.8M and a clean swing from loss to profit, with adjusted EPS at $0.11 versus a -$0.01 consensus.
Record quarterly bookings of $60.7M lifted effective backlog toward $100.6M, with demand spanning AI processors, silicon photonics, and power semiconductor burn-in systems.
Management guided fiscal 2027 revenue to $130–$150M, implying 160%–200% growth and 18%–22% non-GAAP margins, far ahead of roughly $85M Street expectations.
More than $8M in new silicon carbide burn-in orders tied to China EV expansion and a top-two global automaker sharpen AEHR’s leverage to the EV power chip cycle.
Shares ripped roughly 27%–31% to around $91 intraday as Lake Street, Craig-Hallum, and Freedom Broker all raised AEHR price targets into the $110–$125 range, flagging a major growth inflection.

Quick Financial Overview

AEHR has shifted from a slow grind to a fast rollercoaster. The stock’s multi-day chart shows that once AEHR broke out from the mid-$60s in early July 2026, momentum kicked in hard. A consolidation around $72–$84 quickly morphed into a violent spike, with AEHR touching $110.20 on 2026/07/15 before closing that day near $87.79. That is classic squeeze-and-fade behavior after a news shock.

Under the hood, the numbers back the move. Fiscal Q4 revenue of $18.8M grew 33% year over year and slightly topped expectations, but the real surprise was profitability. AEHR posted $0.11 in adjusted EPS versus a -$0.01 consensus, swinging from a loss a year earlier. Record bookings of $60.7M and an effective backlog around $100.6M give traders visibility that this is not a one-quarter fluke.

More Breaking News

At the same time, key ratios show a high-expectation name. A price-to-sales near 59 and price-to-book over 19 mean AEHR is richly valued, while free cash flow has recently been negative and operating cash flow slightly in the red. The balance sheet, though, is strong: current ratio around 11, minimal debt, and substantial cash. For traders, that mix screams “high-growth story stock” with room to run but zero margin for execution missteps.

Why Traders Are Watching AEHR’s Growth Inflection

AEHR is suddenly front and center on momentum screens for a simple reason: the story just changed gears. The company did not just beat earnings; it laid out a roadmap that re-anchors how the market thinks about its future.

Management now guides fiscal 2027 revenue to $130–$150M, implying 160%–200% year-over-year growth from prior levels. For a small-cap equipment maker, that is hypergrowth territory. AEHR is targeting 18%–22% non-GAAP net margins alongside that ramp, tying the outlook directly to structural themes traders understand well: AI data centers, silicon photonics, and power semiconductors like SiC and GaN. When a company says it expects revenue to roughly triple versus prior Street expectations of about $85M, the market listens.

The demand signals behind that guidance look tangible, not fluffy. AEHR booked more than $8M in fresh silicon carbide wafer-level burn-in orders, including a big follow-on from its lead SiC customer supporting expanding EV programs in China and a qualification order from one of the world’s top two automakers for next-gen EVs. That places AEHR deeper inside the EV power semiconductor supply chain.

On the AI side, AEHR secured a follow-on FOX-XP wafer-level burn-in system order from its lead silicon photonics customer, tied to devices used in AI optical interconnects for hyperscale data centers. That repeat business matters — it tells traders AEHR’s technology is being pulled, not pushed, into real, scaling production.

Wall Street has taken notice. Lake Street doubled its AEHR price target to $110, Craig-Hallum lifted its target to $125, and Freedom Broker upgraded AEHR to Buy while raising its target to $110. Combine that analyst wave with a 26%–31% post-earnings surge to roughly $91 on heavy volume, and you have a textbook growth-inflection re-rating that short-term traders love to trade around.

Conclusion

For active traders, AEHR sits at the crossroads of three hot themes: AI infrastructure, silicon photonics, and EV power semiconductors. The fiscal Q4 print marked a turn from loss to profit, with $18.8M in revenue growing 33% and EPS crushing expectations. Record bookings of $60.7M, an effective backlog near $100.6M, and cash above $100M after an equity raise give AEHR runway to chase the aggressive fiscal 2027 revenue goal of $130–$150M.

But this is not a low-risk story. Valuation is steep, free cash flow has been negative, and expectations are now sky-high after AEHR shares spiked into the $90s and briefly tagged $110. When a stock prices in a 160%–200% growth path, any stumble in orders or margins can trigger sharp downside. AEHR’s daily chart already shows wide intraday ranges and quick reversals — ideal for disciplined traders, dangerous for those who chase late.

The educational takeaway is simple: study AEHR as a case study in how narrative, numbers, and price action line up at a growth inflection. As Tim Sykes often says, “The pattern repeats, but you have to be prepared.” As Tim Bohen, lead trainer with StocksToTrade says, “I focus on what a stock is doing, not what I want it to do. Let the stock prove itself before you make a move.”. AEHR is giving traders a live-fire example of that pattern in real time — big catalyst, big move, and now a higher bar every quarter from here.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!